639089-54-6

Basic information

• Product Name: Tozasertib
• Synonyms: Cyclopropane carboxylic acid {4-[4-(4-methyl-piperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino) -pyrimidin-2ylsulphanyl]-phenyl}-amide;VX-680/MK-0457;N-(4-(4-(5-methyl-1H-pyrazol-3-ylamino)-6-(1-methylpiperidin-4-ylamino)pyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide;MK 0457;N-[4-[[4-(4-Methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]cyclopropanecarboxamide;Tozasertib;VX 680;Cyclopropanecarboxamide, N-(4-((4-(4-methyl-1-piperazinyl)-6-((5-methyl-1H-pyrazol-3-yl)amino)-2-pyrimidinyl)thio)phenyl)-
• CAS NO: 639089-54-6
• Molecular Formula: C₂₃H₂₈N₈OS
• Molecular Weight: 464.59
• Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals;Mutagenesis Research Chemicals;Pharmaceuticals;A multikinase inhibitor.;Inhibitor;Inhibitors
• Mol File: 639089-54-6.mol

Chemical Properties

• Appearance: /
• Density: 1.4 g/cm³
• Refractive Index: 1.708
• Storage Temp.: 2-8°C
• Solubility: Soluble in DMSO (up to 100 mg/ml).
• PKA: 14.09±0.70(Predicted)
• Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months.
• CAS DataBase Reference: Tozasertib(CAS DataBase Reference)
• NIST Chemistry Reference: Tozasertib(639089-54-6)
• EPA Substance Registry System: Tozasertib(639089-54-6)

Safety Data

• Hazardous Substances Data: 639089-54-6(Hazardous Substances Data)

Usage

Uses

Used in Cancer Treatment:
Tozasertib is used as a multikinase inhibitor for cancer treatment. It effectively inhibits the proliferation of various cancer cell lines, particularly clear cell renal carcinoma, with IC50s of less than 10 μM. In a rodent model of cancer, Tozasertib blocks tumor growth at a dosage of 80 mg/kg, inhibiting histone H3 phosphorylation and increasing apoptosis. By depleting Aurora kinase activity, it disrupts bipolar spindle formation during mitosis, leading to cell cycle arrest at the G2/M phase.

Biochem/physiol Actions

VX-680 is an ATP site-targeting potent aurora kinase inhibitor (Aurara A/B/C Ki(app) = 0.6/18/4.6 nM) that affects FLT3, BCR-Abl, BCR-Abl (T315I), Lck, ITK, Src, and Fyn only at higher concentrations (Ki(app) = 30, 30, 42, 80, 220, 350, 520 nM, respectively) and exhibits little inhibitory potency toward 52 other kinases (Ki(app) >1 μM). VX-680 exhibits potent antiproliferation activity in a wide variety of cancer cultures (IC50 from 15 to 113 nM) as a result of cell cycle arrest and apoptosis induction, as well as causes tumor retardation (by 98% on day 13; 75 mg/kg b.i.d i.p.; HL-60 in mice) and regression (2 mg/kg/h 3 d/wk i.v. infusion; HCT116 in rats) in vivo. Crystallography data reveal a tight association of VX-680 with a hydrophobic pocket present only in a closed, inactive kinase conformation, which forms the basis of its selectivity profile, including its activity toward wild-type and the Imatinib-resistant (T315I) Abl.

References

1) Harrington et al. (2004), VX-680, a potent and selective small molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo; Nat. Med., 10 262 2) Fei et al. (2010), Activity of the Aurora kinase inhibitor VX-680 against Bcr/Abl-positive acute lymphoblastic leukemias; Mol. Cancer Ther., 9 1318 3) Dewerth et al. (2012), In vitro evaluation of the Aurora kinase inhibitor VX-680 for Hepatoblastoma; Pediatr. Surg. Int., 28 579

InChI:InChI=1/C23H28N8OS/c1-15-13-20(29-28-15)25-19-14-21(31-11-9-30(2)10-12-31)27-23(26-19)33-18-7-5-17(6-8-18)24-22(32)16-3-4-16/h5-8,13-14,16H,3-4,9-12H2,1-2H3,(H,24,32)(H2,25,26,27,28,29)

Upstream product

• 109-01-3 1-methyl-piperazine 
• 639090-55-4 N-[4-({4-chloro-6-[(3-methyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}sulfanyl)phenyl]cyclopropane carboxamide 
• 639090-54-3 (N-(4-mercaptophenyl)cyclopropylcarboxamide) 

Relevant articles and documents

Kinase inhibition and anticancer therapy

This invention relates to novel uses for Compound E in the treatment of diseases, in particular cancer, associated with aberrant kinase expression.

A NOVEL LACTIC ACID FORMULATION OF MK-0457 USEFUL FOR THE TREATMENT OF CANCER

A lactic acid formulation, and a process to prepare that formulation, of MK-0457 is disclosed:. Such a formulation is useful in the treatment of cancer.

ABL KINASE INHIBITION

The present invention relates to inhibition of AbI kinase.